Table 1.
Baseline characteristics of patients: demograp≡hic, clinical, and laboratorial data (n = 152)
| Age, years | 47.2±17.3 (17–89) |
| Male sex | 79 (52) |
| Type of disease | |
| Crohn disease | 106 (70) |
| Ulcerative colitis | 44 (29) |
| Disease duration, years | 8.4±7.9 (0–45) |
| Current medication | |
| Immunosuppressors | 55 (37) |
| Biologics | 26 (17) |
| Corticosteroids | 26 (17) |
| Surgery | 33 (21.7) |
| Inpatients | 18 (11.8) |
| Crohn disease locationa | |
| L1 | 41 (31.7) |
| L2 | 14 (13.2) |
| L3 | 51 (48.1) |
| L4 | 17 (16) |
| Crohn disease behaviora | |
| B1 | 58 (54.7) |
| B2 | 22 (20.8) |
| B3 | 26 (24.6) |
| Perianal disease | 22 (20.8) |
| Ulcerative colitis extenta | |
| E1 | 9 (20.5) |
| E2 | 17 (38.7) |
| E3 | 18 (40.8) |
| C-reactive protein, mg/dL | 0.75±1.8 |
| Sedimentation rate, mm/h | 24.1±23 |
| Hemoglobin, g/dL | 13.4±1.8 |
| Fecal calprotectin, mg/kg | 728±1200 |
| Harvey-Bradshaw index | 2.7±3 |
| Truelove and Witts, mild/moderate/severe | 7/8/2 |
Values are means ± standard deviations (ranges) or n (%) unless otherwise indicated.
a
According to the Montreal Classification.